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Summary
Although it is clear that apoE plays an important role
in the genetics of late-onset Alzheimer disease (AD), ev-
idence exists that additional genes may play a role in
AD, and estimates of the total contribution of apoE to
the variance in onset of AD vary widely. Unfortunately,
little information is available on the number and con-
tribution of additional genes. We estimated the number
of additional quantitative-trait loci and their contribu-
tion to the variance in age at onset of AD, as well as
the contribution of apoE and sex, in an oligogenic seg-
regation analysis of 75 families (742 individuals) ascer-
tained for members with late-onset AD. We found evi-
dence that four additional loci make a contribution to
the variance in age at onset of late-onset AD that is
similar to or greater in magnitude than that made by
apoE, with one locus making a contribution several
times greater than that of apoE. Additionally, we con-
firmed previous findings of a dose effect for the apoE
4 allele, a protective effect for the 2 allele, evidence
for allelic interactions at the apoE locus, and a small
protective effect for males. Furthermore, although we
estimate that the apoE genotype can make a difference
of 17 years in age at onset of AD, our estimate of the
contribution of apoE (7%–9%) to total variation in on-
set of AD is somewhat smaller than that which has pre-
viously been reported. Our results suggest that several
genes that have not yet been localized may play a larger
role than does apoE in late-onset AD.
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Introduction
The search for novel genetic loci affecting liability for
Alzheimer disease (AD [MIM 104300]) is proceeding,
but there is little information on how many AD loci
there may be. To date, four such genes have been con-
clusively identified. Three of these—APP, PS1, and
PS2—have been linked to rare, autosomal dominant
forms of AD that generally have an early onset (Goate
et al. 1991; Schellenberg et al. 1992; Levy-Lahad et
al. 1995a, 1995b; Sherrington et al. 1995). Only one,
apoE, has been associated, in multiple studies, with
common late-onset AD (Pericak-Vance et al. 1991;
Saunders et al. 1993). The apoE gene has three al-
leles—2, 3, and 4—with the 3 allele being most
common. The 4 allele has been associated with high
risk for AD, relative to the 3 allele, in a large number
of studies (e.g., Corder et al. 1993; Jarvik et al. 1995;
Levy-Lahad et al. 1998), whereas a smaller number
of studies have reported evidence indicating that the
less-common 2 allele may have a protective effect
(Corder et al. 1994; Jarvik et al. 1995). A number of
other studies have not estimated an effect for the 2
allele, since their sample sizes for this allele were
small. Indeed, the protective effect for 2 was con-
firmed in a reanalysis that combined a large number
of individuals from multiple studies (Farrer et al.
1997).
Although most studies agree that genetic factors other
than apoE play a role in late-onset AD, estimates of the
relative contribution, to AD risk, of apoE versus these
other factors vary widely. One study estimates that apoE
accounts for 50% of the “predicted total genetic effect”
(Roses et al. 1995), whereas others estimate that apoE
accounts for 10%–15% of the total variance in age at
onset (Bennett et al. 1995; Slooter et al. 1998). These
different estimates may, in fact, be slightly closer together
than they appear: the genetic variance (VG) is only a
component of the total variance (VP). In a twin study,
Bergem et al. (1997) estimated the heritability (narrow
sense: VA /VP, where VA is the additive genetic variance)
for AD to be 0.6. It is also possible to estimate, by use
Daw et al.: Number of Alzheimer Disease Trait Loci 197
of the data of Bergem et al. (1997), that the fraction of
the total genetic variance (broad sense: VG /VP) has a
range of 0.76–0.83. However, since Bergem et al. (1997)
do not allow for any censoring and since only a few
years have passed since diagnosis of the discordant MZ
twin pairs (Bergem and Lannfelt 1997), the broad-sense
heritability could well be larger. These results indicate
that 30% of the total variance in AD—and possibly
70%—is explained by unidentified genetic loci.
Clearly, 30%–70% is a large fraction of the total var-
iance, but our ability to localize genes contributing to
this variance will be determined by the number of such
genes and by the contribution of each. If there is a single
gene accounting for this variance, that gene should be
fairly easy to localize. In fact, it would be surprising if
such a single gene existed, since several complete genome
screens (Pericak-Vance et al. 1998; Kehoe et al. 1999)
have failed to produce any LOD scores 13 for such a
gene. On the other hand, if there are many genes of small
effect, localization of these genes may prove to be in-
tractable. An estimate of the number of additional genes
can give us an indication of how fruitful the search for
additional AD genes will be.
In the present study, we estimated the number and
effects of additional genes on age at onset of AD, by
performing a Monte Carlo Markov chain (MCMC) ol-
igogenic segregation analysis on a collection of families
with late-onset AD. This study makes complete use of
the available family data. The number of additional
quantitative-trait loci (QTLs) involved in age at onset
of AD and the relative contributions of each QTL to the
variance in age at onset of AD were estimated, while
both controlling for and estimating the effects of apoE
and sex. Thus, the current analysis also provides a new
estimate of the effects of apoE genotype, while control-
ling for the effects of the other genes and, at the same
time, making complete use of the family data. Previously,
most estimates of the effects of apoE have been from
case-control studies or from family studies treated as
case-control studies (Corder et al. 1993; Jarvik et al.
1995; Slooter et al. 1998). In such studies, it is impossible
to account for the effects of other genes, since the in-
dividuals studied are unrelated (or are assumed to be so)
and since other genes involved in late-onset AD have
not been conclusively identified. Although our estimates
of the effects of apoE have some similarities to previous
estimates, we estimate that there are four QTLs, in ad-
dition to apoE, that have effects that are as large as or
larger than those of apoE.
Subjects and Methods
Sample
Individuals in 75 families (including two Volga Ger-
man families) with no known PS1, PS2, APP, or TAU
mutations were evaluated either by the University of
Washington Alzheimer’s Disease Research Center, the
Oregon Health Sciences University Alzheimer’s Disease
Center, or the University ofMinnesota Alzheimer disease
research group. Informed consent was obtained from all
subjects. The families contained a total of 742 individ-
uals, with a family-size range of 4–53 individuals. apoE
genotypes were available for 419 individuals. Of these
individuals, 203 had an age at onset of AD (affected),
201 had a censoring age at which they were last known
to be free of AD (unaffected), and 15 had missing phe-
notype information. Individuals were considered to be
missing phenotype data for this analysis if information
on either age (age at onset of AD or censoring age) or
affectation status was unavailable. Phenotypic data were
available for 600 individuals, of whom 282 were af-
fected and 318 were unaffected. Living affected individ-
uals met published criteria for the clinical diagnosis of
AD (McKhann et al. 1984). For deceased individuals
without autopsies and for five families whowere referred
from outside our centers and who were not examined
by our personnel, the diagnosis of probable AD was
established on the basis of detailed medical records that
often included consultations by neurologists, neuro-
psychological testing, computed tomography (CT) or
magnetic-resonance imaging (MRI) of the brain, and
laboratory testing excluding other causes of dementia.
For the sample used here, the mean age at onset was
years, with an individual-onset range of70.6 7.9
40–89 years. The range of mean onset within each in-
dividual family was 63–82 years, and 66 of the 75 fam-
ilies had at least one member with a case of AD con-
firmed at autopsy, with a total of 132 autopsies
conducted in the families. Neuropathologic confirma-
tion of the diagnosis met the criteria published by The
Consortium to Establish a Registry for Alzheimer’s Dis-
ease (CERAD; Mirra et al. 1991) and The Ronald and
Nancy Reagan Research Institute of the Alzheimer’s As-
sociation/National Institute on Aging Working Group
(1998). apoE genotypes were determined by use ofmeth-
ods described elsewhere (Hixson and Vernier 1990).
Statistical Methods
To estimate the number of trait loci and the effects of
each such locus, the effects of each apoE genotype, and
the effect of sex on age at onset of AD, we applied the
MCMCmethods described elsewhere (Heath 1997;Daw
et al. 1999). With the use of these methods, age at onset
is modeled as a censored quantitative trait while an ol-
igogenic segregation analysis is performed. Effectively,
this is a survival analysis in which the failure curves for
each covariate and genotypic group are cumulative nor-
mal distributions with the same variance. By using the
term “covariate and genotypic group,” we mean to de-
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scribe all individuals who share a particular multilocus
genotype at all QTLs and who share a common value
for each covariate. Such groups may also include indi-
viduals for whom the apoE genotype and other genetic
data are probabilistically inferred from data on other
family members. This inference effectively increases our
sample size beyond the 419 individuals for whom apoE
genotype is available. With use of this model, age at
onset is given by: where Mky = MXb S Q a  e,i=1 i i
is the “baseline” age at onset, X is the incidence matrix
for covariate effects (i.e., a matrix indicating the values
at all the covariates; the entries for discrete covariates
will be 0’s or 1’s), b is the vector of covariate effects,
Qi is the incidence matrix for the effects of QTL i, ai is
the vector of effects for QTL i, e is the normally dis-
tributed residual effect, and k is the number of QTLs
currently estimated. All these parameters, with the ex-
ception of the elements of X determined by the data, are
estimated by use of an MCMC process, as detailed else-
where (Heath 1997; Daw et al. 1999). In brief, this pro-
cess samples configurations of model parameters ran-
domly but in such a way that these configurations are
sampled with a frequency that is proportional to their
posterior probability. Thus, after many iterations of this
sampling process, the sampledmodel configurations pro-
vide an estimate of the posterior probability distribution
over the space of possible parameter configurations. In
the analyses presented here, this process was run for
500,000 iterations, and values from every 5th iteration
were retained for estimation of posterior distributions.
Covariates of age at onset can be continuous (e.g.,
weight, height, and blood pressure) or discrete (e.g.,
sex, ethnic group, and country of birth), and they can
include genotype at known genes or candidate genes.
Such “genetic covariates” are useful because they al-
low the known mutation status to be used in the es-
timation of genotypic effects for a loci. Also, whereas
the basic QTL model assumes that a locus is diallelic,
a QTL modeled as a covariate can have any number
of alleles. Furthermore, since the effect of each ge-
notype at a genetic covariate is estimated indepen-
dently, no restrictive assumptions are made with re-
spect to allelic interactions at a genetic covariate
locus. For example, the estimates of the effects of the
apoE 3/3 and apoE 4/4 genotypes do not impose
restrictions either on each other or on the estimate of
the effect of the apoE 3/4 genotype.
We also considered sex to be a covariate. An additive
effect was estimated for males, with the female effect
estimated as the baseline. In contrast to the apoE co-
variate, sex is a relatively simple covariate, with only
two values and nomissing data. As with the other effects,
the sex effect was estimated to be an additive effect—that
is, the years’ difference between the average onset in
males and that in females, after controlling for all other
estimated effects.
In addition to providing estimates of the effects of sex
and apoE, use of thisMCMCmethod allows us tomodel
the effects of additional genes that may contribute to
AD. This not only gives us an estimate of the number
of additional genes involved in late-onset AD, but it also
gives us estimates of the effects of apoE while controlling
for the additive effects of other genes and sex. All four
possible models defined by sex and additional QTLs
were considered: the effects of apoE genotypes on age
at onset were estimated both with and without sex as a
covariate and both with and without modeling of ad-
ditional QTLs. In the analyses where additional QTLs
were allowed, we estimated the variance attributed to
each of these QTLs as well as the number of such QTLs.
We then compared the variances of these QTLs to the
variance estimated for apoE, to examine the effect sizes
(i.e., the attributable phenotypic variance) for other pu-
tative late-onset AD genes and to examine the overall
contribution of apoE to the variance of late-onset AD.
For purposes of comparison and for evaluation of our
methods, a Kaplan-Meier survival analysis was done.
Separate survival curves were computed for each apoE
genotype. We were then able to compare these results
both with the results that we obtained using the MCMC
methods and with those obtained by other researchers
using Kaplan-Meier survival analysis.
Results
Number of QTLs
Our MCMC analysis of the 75 available families with
late-onset AD found evidence for a number of genes, in
addition to apoE, affecting age at onset of AD (table 1).
The number of additional genes was estimated to be in
the range of four to seven (fig. 1), with four of the QTLs
generally having a variance that was as large as or larger
than that of apoE. Of these four additional QTLs, one
was substantially larger than the rest, accounting for
150% of the total genetic variance (fig. 2 and table 1).
This largest QTL was estimated to be an overdominant
locus—that is, the effect of the heterozygote genotype
was estimated to be the most detrimental. The frequency
of the common allele at this locus was estimated to be
.60 (.07 SD), and, with the common homozygote fixed
as baseline (zero effect), the heterozygote had an esti-
mated effect of7.8 years (3.0 SD) and the less-frequent
homozygote had an estimated effect of 28.8 years
(12.3 SD). The next three QTLs all had highly overlap-
ping distributions, and they accounted for ∼13%, ∼8%,
and ∼5% of the genetic variance (square-root variance
∼3.5–6 years). apoE accounted for 7%–9% of the ge-
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Table 1
Partitioning of Variance of Age at Onset of AD
PERCENT OF TOTAL VARIANCE (SQUARE-ROOT VARIANCE)





Other QTLs apoE and Sex apoE Only
Environment/residual 1.5% (1.8 years) 2.5% (2.5 years) 84.7% (10.9 years) 85.5% (10.9 years)
Sex .7% (1.2 years) ) .5% (.9 years) )
Total genetic variance 97.9% (14.8 years) 97.5% (15.8 years) 14.7% (4.5 years) 14.5% (4.5 years)
apoE 9.2% (4.5 years) 6.6% (4.1 years) 14.7% (4.5 years) 14.5% (4.5 years)
Total variance, other QTLsa 88.7% (14.1 years) 90.9% (15.3 years) ) )
1stb 57.1% (11.3 years) 64.0% (12.7 years) ) )
2d 13.5% (5.4 years) 13.4% (5.8 years) ) )
3d 8.1% (4.2 years) 7.6% (4.4 years) ) )
4th 5.7% (3.5 years) 5.1% (3.6 years) ) )
5th 3.1% (2.6 years) 2.1% (2.3 years) ) )
6th 1.4% (1.8 years) .7% (1.4 years) ) )
7th .4% (1.0 years) .2% (.7 years) ) )
Smaller QTLs !.1% (.2 years) !.1% (.3 years) ) )
Total variance: 224.4 256.6 140.1 138.5
a Average total effect of all QTLs other than apoE.
b Average effect of each QTL (other than apoE) ranked by effect size.
Figure 1 The posterior distributions for the number of QTLs,
in addition to apoE, affecting age at onset of AD. Distributions were
generated in each of the four analysis runs in which additional QTL
effects were modeled: 3 runs with apoE and other QTLs (run 1 [un-
broken line with diamonds], run 2 [dashed line with squares], and run
3 [dotted line with triangles]) and 1 run with apoE, sex, and other
QTLs (dashed and dotted line with X’s).
netic variance (square-root variance 4–4.5 years). Be-
cause of the overlap, we cannot exclude the possibility
that the actual genes being modeled by the 2d-, 3d-, and
4th-largest QTLs are responsible for the same propor-
tion of the actual trait variance as is apoE. The largest
QTL, however, was clearly estimated to have larger var-
iance than apoE, with the variance attributed to the larg-
est QTL being greater than that attributed to apoE in
199.9% of the sampling iterations.
apoE Effects
In addition to providing evidence for multiple QTLs,
our analysis provides new estimates for the effects of
each apoE genotype. These new estimates clearly con-
firm that apoE genotype affects age at onset of AD. The
extreme genotypes—4/4 and 2/3—differ in mean
age at onset by ∼17 years (no individuals with the apoE
2/2 genotypes were available in our data set) (table 2
and fig. 3). The apoE 3 and 4 alleles appear to act
approximately additively, with the 3/4 genotype fall-
ing approximately midway between the 3/3 and 4/
4 genotypes. The 2/3 genotype is clearly protective,
relative to the other genotypes, with mean onset occur-
ring 6–8 years later than that for the genotype 3/3,
which has the next oldest onset. The 2/3 estimate has
a large SD (4–5 years) as a result of the small number
of such individuals in our sample. The SD for the 2/4
genotypic effect is also large as a result of the small
sample size. This latter distribution spans those for the
4/4, 3/4, and 3/3 genotypes, although its mean is
consistently placed between the 3/4 and 3/3 geno-
typic means. To which of these means the 2/4 geno-
typic mean is nearest depends on whether the effects of
additional QTLs are allowed: when no other genes are
modeled, the 2/4 genotype mean is estimated to be
closer to the 3/3 genotypic mean; when other genes
are modeled, the 2/4 genotype mean is estimated to
be closer to the 3/4 genotypic mean.
Comparison of the results of our MCMC analysis of
the effects of apoE on age at onset of AD (table 2) with
results that we obtained from Kaplan-Meier survival
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Figure 2 Posterior distributions for the phenotypic effect
(square-root variance) attributed to apoE (unbroken line) and to each
of the four largest QTLs (dotted lines and broken lines). Square-root
variance is in years.
Table 2
Means and SDs for Estimated Covariate Effects





( )n = 111
3/4
( )n = 207
2/4
( )n = 67
3/3
( )n = 19
2/3
( )n = 15
Male
( )n = 331
apoE, sex, other QTLs 6.8 (1.3) 1.6 (.7) .6 (3.4) 4.2 (.9) 10.0 (5.2) 2.1 (1.2)
apoE, other QTLs 5.3 (1.5) 1.5 (.7) 1.0 (3.7) 3.1 (.9) 11.8 (4.4) )
apoE, sex 6.3 (1.4) 1.9 (.8) 2.5 (3.7) 3.8 (1.1) 11.3 (4.0) 1.3 (1.1)
apoE 6.2 (1.4) 2.0 (.8) 2.3 (3.7) 3.8 (1.1) 11.2 (4.0) )
a Of posterior distribution of effects, relative to sample mean.
analysis (table 3) showed that the twomethods produced
remarkably similar results. The years effect estimated by
survival analysis was within one standard error of the
effects estimated by use of MCMC methods for each
genotype. The difference between the 4/4 and 2/3
genotypes was very slightly greater in the Kaplan-Meier
analysis than in the MCMC analyses (18.2 years vs.
15.9–17.6 years). Although the results of the two meth-
ods of estimation of the effects of apoE are quite similar,
the MCMC methods use all family data, can estimate
many effects in addition to those of apoE, and can also
be used to localize genes when marker data are available.
Sex Effect
Sex also appears to affect age at onset of AD. The
mean onset for males was estimated to be 1–2 years later
than that for females, after accounting for other additive
effects. Although this effect is small, the posterior prob-
ability that this effect is positive is 95%. The only dis-
cernible effect of the inclusion of sex was an increase in
the difference between the 3/3 and 4/4 genotypes in
the models allowing for the effects of other QTLs (table
2), suggesting an interaction between sex and apoE ef-
fects.
The estimated apoE effects were consistent across
three MCMC-analysis runs of the same model. With use
of a stochastic analysis method, such as the one used in
the present study, an important issue is the stability of
the results under different starting conditions. Table 4
shows the stability of the estimates of the effects of apoE
in separate analysis runs of 500,000 iterations each, in
which the effects of apoE genotype and other QTLs are
modeled. The range of values between these runs is
smaller for each effect than is the range between models
shown in table 2. In particular, this indicates that the
larger differences in apoE-genotype effects among mod-
els seen in table 2 are likely to reflect the different mod-
els, rather than the stochastic process (i.e., Monte Carlo
error), although all the differences seen between models
are within 1 SD of each other.
The estimate of the number of QTLs appears to be
more variable (fig. 1), but the estimates of the effect sizes
for the largest four QTLs were consistent in iterations
with 4 QTLs present. The remaining QTLs all tended
to have a smaller effect than did apoE and, in some cases,
the effect was very small. In iterations with seven QTLs,
for example, the effects attributed to the two smallest
QTLs modeled are probably too small to be detectable
in linkage analyses of this data. Some of these smaller
QTLs may be artifacts of the MCMC analysis process.
In any case, in all runs, the posterior probability of the
presence of four to seven additional QTLs was greater
than the posterior probability of the presence of any
other number of QTLs.
Discussion
Our analysis of familial late-onset AD data provides
novel evidence that four additional genes make a con-
tribution to age-at-onset variation that is as large as or
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Figure 3 Posterior distributions for mean effect of each apoE
genotype when the effects of other QTLs, but not the effect of sex,
were modeled. Each curve is generated from 100,000 realizations con-




4/4 3/4 2/4 3/3 2/3
Mean age at onset 71.2 75.2 77.3 81.2 89.4
Effecta 6.4 2.4 .3 3.6 11.8
Standard error (1.3) (.7) (2.8) (1.3) (4.8)
a Data represent deviation from overall mean.
larger than that of apoE. This analysis also provides new
estimates of the effects of sex and each apoE genotype.
Our estimates of the relative direction of the effects of
apoE genotypes and sex confirm previous findings and
thus support the use of MCMC methods. However, our
estimate of the proportion of the total variance attrib-
uted to apoE appears to be slightly smaller than previ-
ously reported estimates and places new emphasis on
the role that additional genes may play in late-onset AD.
The results from our oligogenic model suggest that
4 additional QTLs may each account for at least as
much of the variability in age at onset of AD as does
apoE. The true number of genes cannot be precisely
estimated: multiple genes with similar effects segregating
in different families can produce evidence for a single
gene with a larger effect; some other effects, such as
transmissible environment effects, could potentially
mimic genes. Also, an astute reader will have noticed
that, in table 1, the total variance estimated is different,
depending on whether additional QTLs are modeled.
This difference is caused in part by underestimation of
the total phenotypic variance, under the data-censoring
model, when additional QTLs are not allowed. Under-
estimation occurs because, when additional QTLs are
not modeled, the trait values for censored individuals
are constrained to be near those of uncensored individ-
uals, by the assumption of normality in the residual var-
iance. The difference in total variance seen in the two
cases is similar to the difference that one would see be-
tween estimation of total variance in a sample including
only cases and estimation of total variance in a mixed
sample that is more representative of the whole popu-
lation. In addition, the residual variance in the oligogenic
analyses may be underestimated. In data collection, only
families with multiple affected individuals were ascer-
tained, which could bias the estimate of the environ-
mental variance downward.
The overdominance estimated in the largest QTL
could result from a number of factors. The QTL could,
in fact, be overdominant. If this were the case, caution
would be suggested in the use of methods that have high
power only for modes of inheritance in which the het-
erozygote falls between the two homozygotes. Another
possibility is that gene-gene interactions might result in
estimation of an overdominant effect. The degree to
which this is a problem for gene localization will depend
on the degree of the interaction. An additional genetic
reason for estimation of overdominance could be the
presence of multiple alleles at the trait locus. The model
used here allowed for only two alleles at a QTL, so if
the actual trait locus has three or more alleles with dif-
ferent effects, as is the case for apoE, the diallelic model
could cause an overdominant trait to be estimated. Fi-
nally, the results of a previous study (Daw et al. 1999),
showed some overdominance as a result of trait-model
overfitting. This overfitting was not detrimental to lo-
calization of genes.
It might seem surprising that a QTL with the effect
of the largest QTL found here has not already been
localized. If this QTL does in fact exist, there could be
a number of reasons why it has not yet been found. For
a simple overdominant trait—that is, a monogenic dial-
lelic trait where the heterozygotes are affected but the
homozygotes are not affected—with a 60% frequency
for the common allele, the expected identity-by-descent
allele sharing at the disease locus between affected sib-
lings is ∼1.3. We believe that the trait is far more com-
plex than this simple overdominant model, and com-
plications such as the presence of multiple alleles at the
trait locus, the interactions between those alleles, the
presence of other trait loci, and the nongenetic influences
on the trait would all tend to reduce this already modest
identity-by-descent sharing. Thus, to detect such a locus,
marker-allele sharing methods may require a sample far
larger than any that have been collected to date. Alter-
natively, LOD-score methods depend on a model for the
disease locus and are known to perform poorly when
the model is wrong. Overdominant models are not gen-
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Table 4
Effects of apoE Genotypes Estimated in Three Separate Analysis
Runs Modeling apoE and Other QTL Effects
MEAN (SD) ESTIMATED EFFECT OF APOE GENOTYPEa
(years)
RUN 4/4 3/4 2/4 3/3 2/3
1 5.3 (1.5) 1.5 (.7) 1.0 (3.7) 3.1 (.9) 11.8 (4.4)
2 5.4 (1.6) 1.6 (.8) .6 (4.1) 3.2 (1.1) 11.4 (4.4)
3 5.2 (1.6) 1.3 (.8) 1.2 (3.6) 3.0 (1.2) 10.7 (4.2)
a Of posterior distribution of effects, relative to sample mean.
erally considered when LOD-score linkage analysis is
done. If the locus identified here exists, the models used
previously may have resulted in low power to detect
linkage.
There are several approaches that may be able to lo-
calize this trait locus. When we restrict these MCMC
methods to prevent them from searching outside the tra-
ditional dominant-to-recessive range, these methods
have greater difficulty in identification of the putative
QTL reported here (data not shown). Although a mul-
tiallelic model with interactions could be the true model,
it is possible that a single-locus overdominant model will
fit the data sufficiently well to localize the gene. When
analyzing complex traits, LOD-score methods may ben-
efit from the consideration of a wider range of trait-
locus models. Variance component methods, which es-
timate additive and dominance components for a locus,
might also be able to localize such a complex locus. We
expect that trait loci detected by means of segregation
analysis with use of these MCMC methods can also be
localized by means of combined segregation and linkage
analysis with these methods.
Our results for the apoE genotypic effects confirmed
the generally accepted findings of a dose effect for the
4 allele with respect to the 3 allele (Corder et al. 1993)
and also found shifts in age at onset of AD that corre-
spond exactly to the order of the liabilities for AD for
each genotype found in some previous studies (Jarvik et
al. 1995; Farrer et al. 1997). Consistent with the results
of previous reports (Corder et al. 1994), we found that
the 2/3 genotype has a strong protective effect. How-
ever, the mean of the posterior distribution for the 2/
4 genotypic effect was found to be between that of 3/
3 and 3/4 in all our analyses, suggesting that the
protective effect of the 2 allele may be largely overcome
by the detrimental effect of the 4 allele. Unfortunately,
the large overlap that occurs in the distributions of the
3/4 and 3/3 genotypes indicates that a sample of
families including a larger number of individuals with
the 2/4 genotype than the number seen in the present
study is required to resolve the relative effect of this
genotype. Additional difficulties in obtaining an esti-
mation of the 2/4 effect may arise if there are inter-
actions with other loci or if there is linkage disequilib-
rium with other sites either in or near apoE. Such
interactions are suggested by the observation that the
mean for 2/4 is closer to that of 3/4 when other
QTLs are included in the model and that the mean for
2/4 is closer to 3/3 when other QTLs are not in-
cluded. Since previous methods of analysis have not ex-
plicitly incorporated additional QTLs into the analysis,
this observation of evidence for interactions between
apoE and other factors is new. Results described else-
where (Roses et al. 1994) have shown a difference sim-
ilar to that found in the present study, with regard to
median age at onset for the different apoE genotypes.
The difference between the 4/4 and 2/3 genotypes
found by Roses et al. (1994) was slightly 115 years,
which is very close to our finding. This agreement with
the results of previous studies increases the confidence
in these and other estimates of the effects of apoE, even
though other studies did not use full pedigree data, as
was done in the present study.
Allelic interaction between 2 and the other apoE al-
leles is suggested by the results of the present study.
Unfortunately, we could not estimate the effects of the
2/2 genotype, since there were neither any sampled
individuals with the 2/2 genotype nor any individuals
in whom this genotype could be clearly inferred. How-
ever, the placement of the 2/3 and 2/4 effects, rel-
ative to the placement of other effects, suggests that the
2 allele does not interact additively with both the 3
and 4 alleles. In a strictly additive system, one would
expect either the protective effect of the 2/3 genotype
to be smaller or the 2/4 genotype to have a larger
mean than the 3/3 genotype. Since these results suggest
allelic interaction, in the search for additional AD genes,
it may be important to account for apoE genotype, as
is done here, rather than use a model based on the simple
presence or absence of each of the alleles.
While some previous discussion has focused on
whether apoE is a causative locus or a modifier locus
for AD, this distinction may be semantic and is irrelevant
under the model used here. Our model assumes that
everyone will eventually get AD if they live long enough
and that the QTLs simply shift the mean age at on-
set—that is, a highly protective genotype would be mod-
eled as shifting the mean age at onset to a much later
age. The ramifications and limitations of this model are
discussed elsewhere (Daw et al. 1999). With a disease
that occurs as late in life as does late-onset AD, there is
no question that the difference of 16–17 years found
between the 4/4 and 2/3 genotypes represents an
important factor in AD liability. Delaying the onset by
even as much as a few years would greatly reduce the
number of clinical AD cases.
Finally, we confirmed evidence for a protective effect
for AD in males. Such a protective effect is consistent
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with findings from previous studies (Payami et al. 1994;
Gao et al. 1998). Although this effect was relatively
small (1–2 years), sex could interact with other risk fac-
tors, thereby making it more significant in some situa-
tions than in others. The precision of the estimates of
covariate effects (sex and apoE in the present study) is
affected by the number sampled in each covariate group,
and the estimates of these effects, relative to the mean,
are also affected by the number in each group. However,
different numbers in each group do not bias the estimates
of the effect of each covariate group relative to each
other. For example, the estimate of the male effect versus
the female effect is not biased by different numbers of
male and female family members sampled. In addition,
the estimates are not biased on the basis of whether
family members are unaffected or have observed ages of
onset, since the censored-data model used (Daw et al.
1999) accounts for this. The differences seen in the es-
timates of the apoE effects, in a comparison of the model
including apoE, sex, and other QTLs with the model
including just apoE and other QTLs, suggest an inter-
action between apoE genotype and sex. This finding is
consistent with previously reported results for the risk
of AD in a case-control study (Jarvik et al. 1995).
Although these results clearly confirm the important
role of apoE in late-onset familial AD, they also suggest
that apoE represents only 7%–9% of the total variance
in age at onset of familial AD and that it is but one of
several important genes. There appear to be 4 addi-
tional QTLs that have an effect, at least on a par with
that of apoE, on age at onset of familial AD. One of
these QTLs appears to have a much greater effect. These
results indicate that MCMC methods should be able to
localize several novel late-onset AD loci, once a full-
genome screen is completed on this data set.
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